Sort   by:  
 Page size 
UnknownMulticenter Real-World Outcomes of Risankizumab in Crohn's Disease: The RESOLVE IG-IBD Study.

Introduction

To assess the effectiveness and safety of Risankizumab (RZB) in a large, nationwide real-world cohort of patients with Crohn's disease (CD).

Methods

We conducted a multicenter, retrospective observational cohort of adults initiating RZB with assessments at weeks 12, 26, a...
S-EPMC13629653 | biostudies-literature
UnknownTocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial.

Background

Tocilizumab blocks pro-inflammatory activity of interleukin-6 (IL-6), involved in pathogenesis of pneumonia the most frequent cause of death in COVID-19 patients.

Methods

A multicenter, single-arm, hypothesis-driven trial was planned, according to a phase 2 design, to study...
S-EPMC7576974 | biostudies-literature
Sort   by:  
 Page size